Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Other Working Capital Changes (2016 - 2025)

Sunshine Biopharma's Other Working Capital Changes history spans 13 years, with the latest figure at -$189082.0 for Q4 2025.

  • For Q4 2025, Other Working Capital Changes fell 141.23% year-over-year to -$189082.0; the TTM value through Dec 2025 reached -$480798.0, down 332.08%, while the annual FY2025 figure was -$480798.0, 332.08% down from the prior year.
  • Other Working Capital Changes reached -$189082.0 in Q4 2025 per SBFM's latest filing, down from -$36168.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $568981.0 in Q1 2024 to a low of -$736637.0 in Q2 2024.
  • Average Other Working Capital Changes over 5 years is -$12443.0, with a median of -$21720.0 recorded in 2021.
  • The largest YoY upside for Other Working Capital Changes was 4490.14% in 2023 against a maximum downside of 1541.65% in 2023.
  • A 5-year view of Other Working Capital Changes shows it stood at -$22268.0 in 2021, then soared by 126.33% to $5863.0 in 2022, then skyrocketed by 4490.14% to $269120.0 in 2023, then soared by 70.39% to $458558.0 in 2024, then crashed by 141.23% to -$189082.0 in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Other Working Capital Changes are -$189082.0 (Q4 2025), -$36168.0 (Q3 2025), and -$115617.0 (Q2 2025).